FDA Says Amgen's Vectibix Promotional Video Is Misleading
The FDA ordered Amgen to stop misleading Vectibix promotion, citing omitted risks including skin toxicity and pulmonary fibrosis.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
The US Food and Drug Administration (FDA) found that Amgen's promotional video for Vectibix was false or misleading, according to Reuters. The regulator said the video left out material risk information, including dermatologic toxicity, infusion reactions and pulmonary fibrosis.
The FDA has ordered Amgen to stop the misleading promotional communications. If the violations are not corrected, the company faces seizure of its products and an injunction.
why it matters
For Amgen investors, this is mainly a regulatory and enforcement risk rather than an immediate hit to revenue. The order concerns the promotion of a single drug, so the broader market impact is limited.
market impact
Amgen: регуляторные риски и возможные санкции за рекламу Vectibix
tags
instruments
sources
- FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure Of Communications — Reuters, 27 October 2026 at 18:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗